Login

JAVELIN PHARMACEUTICALS, INC SEC Filings

Filed On Filing
16 Jul 2010 15-12G
06 Jul 2010 EFFECT
06 Jul 2010 EFFECT
06 Jul 2010 EFFECT
06 Jul 2010 25-NSE
02 Jul 2010 S-8 POS
02 Jul 2010 S-8 POS
02 Jul 2010 S-8 POS
02 Jul 2010 S-3
02 Jul 2010 POS AM
02 Jul 2010 POS AM
02 Jul 2010 Form 4: Kiernan Peter D. Iii, Director

Returned 2,411,848 shares to the issuer ($5.31M) · Disposed of 74,000 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Carr Daniel B, Director

Disposed of 80,494 shares (Tender Offer) ($177K) · Returned 59,524 shares to the issuer ($131K) · Disposed of 1,546,731 Stock Option (right to buy) (Disposition to Issuer) · 1 more

02 Jul 2010 Form 4: Nebgen Georg, Director

Disposed of 100,644 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Flanzraich Neil, Director

Returned 1,000,000 shares to the issuer ($2.2M) · Disposed of 136,604 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Driscoll Martin J, Director

Returned 179,529 shares to the issuer ($395K) · Returned 59,524 shares to the issuer ($131K) · Disposed of 1,449,739 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Mermelstein Fred H, Director

Disposed of 577,316 shares (Tender Offer) ($1.27M) · Disposed of 1,003,052 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Watson Douglas G, Director

Disposed of 20,000 shares (Tender Offer) ($44K) · Disposed of 354,565 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Clegg Jackie M, Director

Disposed of 237,921 Stock Option (right to buy) (Disposition to Issuer)

02 Jul 2010 Form 4: Tulipano Stephen J, CFO and Secretary

Disposed of 10,115 shares (Tender Offer) ($22.3K) · Returned 12,500 shares to the issuer ($27.5K) · Disposed of 464,100 Stock Option (right to buy) (Disposition to Issuer)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support